Member Info for Scinv_temp

Lmao both replies

About the question you asked, this is paid by company capital and the sum given is subtracted from market cap, meaning is a negative drive on the pps. "Trader" lamo

Are you saying this is going to be an ongoing dividend?

Market cap is the biggest obstacle but when we stabilise at 100M or above it should be easier

Nonsense. This is a one off and stup1d one

Dividend is a headwind to momentum, by definition and in essence. Mature companies with limited growth prospects do that. Not saying that cash at hand does not play a role too, but it's not like we have billions.

*Hopefully soon majority will be owned by institutional investors.

*Hopefully soon we majority will be owned by institutional investors.

Looks good except for the shareholder distribution which is ridiculous but I guess it reflects the majority view of the shareholders. Hopefully soon we majority will be owned by institutional investors.

Moaniman

I didn't say AI does not have a place in pharma. It absolutely does. I am saying polb is using iy as a bait as their AI projects have no substance.

Oh yeah people didn't send this "to the moon" (ceo read a comment like that during previous presentation which is a huge red flag) because they missed the rns.

Or, as I said, in this case this is just a buzzword to attract naive investors since the database isn't anywhere near large enough for novel targets. It is hugr in the number of variables but the number of patients is in the hunderds which actually makes things worse. HVO who generated and owns the data uses it properly

Wrong board. Also polb is full of hot air. The real value in hvivos data is predicting disease progression and response to therapy. The AI stuff in this case is used as a buzzword to attract naive investors.

The MMs, sure. Perhaps its the illuminati?

Someone dumped 8M shares at 9am to the PIs waiting for it to "go to the moon" (lmao your ceo even read a comment like this during the Q/A).

BTW I had been waiting for moniman to ask their usual "why is this down after such great news/presentation?" But he failed me this time so I wrote my note anyway :p

Here is an example of using p38i to ameliorate CRS induced by CAR T-cells.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170323/

There are obviously many examples of using p38i to prevent CRS. So much for non obviousness.

A few notes

1. In LPS study volunteers were pretreated with the drug which does not reflect timing of treatment in influenza (you get treatment at onset or after)
2. Metabolic asset with product from AnaBio trial commencement in H1 2023 -> this is laughable the chances of initiating a clinical trial H1 with a new formulation so soon are slim at best.
3. Question of nevelty of using p38i in CRS (around 36 to 37m in the presentation) was answered in contradiction to information on slide 8 where it says CRS has been an area of interest (as discussed here before). In the second part of his answer he clarified that the distinction is shorter treatment window which is laughble and also in contradiction to "non obviousness" also in slide 8. As discussed before, peolle have suggested using p38i in flu/other respiratory viral infections and, innaddition, to prevent adverse effects in CAR T cell therapies. Only route here is to able to obtain ORPHAN drug designation which has not been discussed at all.
4. Cheeky answer to question how many companies were interested when he said a dozen, usual interest means a follow up after initial discussion but hey, this is minor compared to the rest.

My view is you are been taken for a ride with buzzwords and TAMs

Have a great day

Good morning pumpkin

So what of YOU can't believe it? You're a clown, doesn't matter what you believe. The truth is that polb communicated zero material information.